Myocardial perfusion abnormalities in chemical warfare patients intoxicated with mustard gas

  • Ali Gholamrezanezhad
  • Mohsen Saghari
  • Arsalan Vakili
  • Sahar Mirpour
  • Mohammad Hossein Farahani
Original Paper



Mustard agents are of the major chemical agents used during Iran–Iraq war. There are no reports concerning long-term cardiac effects. The aim was to assess the scintigraphic pattern of myocardial perfusion in patients intoxicated with blistering gases.


We analyzed myocardial perfusion scans of 22 consecutive intoxicated patients (21 male and 1 female, all  < 44 years) and compared results with 14 controls. Only those patients and controls were entered whose 10-year risk of coronary artery disease (Framingham criteria) was  <5%. Also only those patients were experimented upon that had currently other confirmed complications of intoxication (respiratory, cutaneous and ocular complications). All patients underwent a 1-day stress and rest protocol using 99mTc-MIBI. Images were assessed visually and quantitatively using Cedars Sinai program.


The prevalence of nonhomogeneity of uptake and left and right ventricular enlargement in both visual and quantitative analyses were higher in the mustard exposed patients than unexposed controls. The prevalence of ischemia was higher in the exposed patients (P < 0.05). Cavity to myocardium ratio, as an established and validated measure of ejection fraction, was also significantly lower in the warfare patients than the controls.


In so far it lies in our knowledge, this is the first report concerning the scintigraphic pattern of myocardial perfusion in mustard intoxicated patients. Based on the results, the pattern of myocardial perfusion in these patients is significantly different from normal controls, which could resemble either coronary artery disease or mild cardiomyopathic changes.


Myocardial perfusion scintigraphy 99mTc-sestamibi Chemical warfare Mustard agents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



We are indebted to Dr. Armaghan Fard-Esfahani, Dr. Davood Beiki, Dr. Babak FallahiSichani, and Dr. Mohammad Eftekhari, (Research Institute for Nuclear Medicine, Shariati Hospital) for their consultations throughout the investigation and their suggestions. Thanks are also extended to the technologists at our institute (especially Mr. Hajami, Mr. Derakhshandeh, and Ms. Abedi) for data acquisition.


  1. 1.
    Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D (2003) Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 45: 1136–1143PubMedCrossRefGoogle Scholar
  2. 2.
    U.S Army Field Manual 3–9, U.S. Navy Publication P-467, U.S. Air Force Manual 355–7, “Potential Military Chemical/Biological Agents and Compounds,” Washington DC; 1990Google Scholar
  3. 3.
    Federation of American Scientists Report: “Special Weapons Primer.” October 21, 1998. Adapted from Chemical Weapons Technology Militarily Critical Technologies list (MCTL) Part II: Weapons of Mass Destruction Technologies. From: FM 8–9, NATO Handbook on the Medical Aspects of NBC Defensive of the Army, the Navy and Air Force, Washington DC; 1996Google Scholar
  4. 4.
    United Nation official reports S/16433(1984), S/17911(1986), and S/18852(1987)Google Scholar
  5. 5.
    Statistic Annals Booklet of the Janbazan Organization (2000) Clinical status of chemical warfare victims. Janbazan Organization, Health and Treatment DepartmentGoogle Scholar
  6. 6.
    Forootan A (1996) Medical notes on the chemical warfare: Part I. Kowsar Med J 1:91–97Google Scholar
  7. 7.
    Thomsen AB, Eriksen J, Smidt-Nielsen K (1998) Chronic neuropathic symptoms after exposure to mustard gas: a long-term investigation. J Am Acad Dermatol 39:187–190PubMedCrossRefGoogle Scholar
  8. 8.
    Norman J (1975) Lung cancer mortality in World War I veterans with mustard-gas injury: 1919–1965. J Natl Cancer Inst 54:311–317PubMedGoogle Scholar
  9. 9.
    Yamakido M, Ishioka S, Hiyama K et al (1996) Former poison gas workers and cancer: incidence and inhibition of tumor formation by treatment with biological response modifier N-CWS. Environ Health Perspect 104(suppl 3):485–488PubMedCrossRefGoogle Scholar
  10. 10.
    Easton DF, Peto J, Doll R (1988) Cancers of the respiratory tract in mustard gas workers. Br J Indust Med 45:652–659Google Scholar
  11. 11.
    Nishimoto Y, Yamakido M, Ishioka S et al (1987) Epidemiological studies of lung cancer in Japanese mustard gas workers. Princess Takamatsu Symp 18: 95–101PubMedGoogle Scholar
  12. 12.
    Tokuoka S, Hayashi Y, Inai K et al (1986) Early cancer and related lesions in the bronchial epithelium in former workers of mustard gas factory. Acta Pathol Jpn 36:533–542PubMedGoogle Scholar
  13. 13.
    Nishimoto Y, Yamakido M, Shigenobu T et al (1983) Long-term observation of poison gas workers with special reference to respiratory cancers. J UOEH 20(suppl):89–94Google Scholar
  14. 14.
    Manning KP, Skegg DC, Stell PM et al (1981) Cancer of the larynx and other occupational hazards of mustard gas workers. Clin Otolaryngol 63:165–170Google Scholar
  15. 15.
    Azizi F, Keshavarz A, Roshanzamir F et al (1995) Reproductive function in men following exposure to chemical warfare with sulfur mustard. Med War 11:34–44PubMedGoogle Scholar
  16. 16.
    Safarinejad MR, Moosavi SA, Montazeri B (2001) Ocular injuries caused by mustard gas: diagnosis, treatment, and medical defense. Mil Med 166:67–70PubMedGoogle Scholar
  17. 17.
    Pleyer U, Sherif Z, Baatz H et al (1999) Delayed mustard gas keratopathy: clinical findings and confocal microscopy. Am J Ophthalmol 128:506–507PubMedCrossRefGoogle Scholar
  18. 18.
    Dahl H, Gluud B, Vangsted P et al (1985) Eye lesions induced by mustard gas. Acta Ophthalmol Suppl 173:30–31PubMedCrossRefGoogle Scholar
  19. 19.
    Balali M (1984) Clinical and laboratory findings in Iranian fighters with chemical gas poisoning. Arch Belg Suppl:254–259Google Scholar
  20. 20.
    Asboe S, Fledelius H (1978) Mustard gas: a medical–ecological problem. Eye and skin injuries in 3 Ostersjo fishermen. Ugeskr Laeger 140:2048–2050PubMedGoogle Scholar
  21. 21.
    Geeraets WJ, Abedi S, Blanke RV (1977) Acute corneal injury by mustard gas. South Med J 70:348–350PubMedGoogle Scholar
  22. 22.
    Blodi FC (1971) Mustard gas keratopathy. Int Ophthalmol Clin 11:1–13PubMedCrossRefGoogle Scholar
  23. 23.
    Momeni AZ, Aminjavaheri M (1994) Skin manifestations of mustard gas in a group of 14 children and␣teenagers: a clinical study. Int J Dermatol 33: 184–187PubMedGoogle Scholar
  24. 24.
    Bullman T, Kang HA (2000) Fifty year mortality follow-up study of veterans exposed to low level chemical warfare agent, mustard gas. Ann Epidemiol 10:333–338PubMedCrossRefGoogle Scholar
  25. 25.
    Olajos EJ, Olson CT, Salem H et al (1998) Evaluation of neutralized chemical agent identification sets (CAIS) for skin injury with an overview of the vesicant potential of agent degradation products. J Appl Toxicol 18:409–420PubMedCrossRefGoogle Scholar
  26. 26.
    Petrali JP, Oglesby-Megee S (1997) Toxicity of mustard gas skin lesions. Microsc Res Technol 37:221–228CrossRefGoogle Scholar
  27. 27.
    Smith KJ, Hurst CG, Moeller RB et al (1995) Sulfur mustard: its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy. J Am Acad Dermatol 32:765–776PubMedCrossRefGoogle Scholar
  28. 28.
    Ghanei M (2001) Late Pulmonary Complications of Mustard Gas Inhalation. Abstract B2, World Congress on Chemical and Biological Terrorism; Dubrovnic, Croatia; April 23–27Google Scholar
  29. 29.
    Aslani J, Ghanei M (1998) A case of unilateral lung collapse in a mustard gas victim. Mil Med 1:49–50Google Scholar
  30. 30.
    Emad A, Rezaian GR (1997) The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 112:734–738PubMedGoogle Scholar
  31. 31.
    Assennato G, Ambrosi F, Sivo D (1997) Possible long-term effects on the respiratory system of exposure to yperite of fishermen. Med Lav 88:148–154PubMedGoogle Scholar
  32. 32.
    Andrew DJ, Lindsay CD (1998) Protection of human upper respiratory tract cell lines against sulfur mustard toxicity by hexamethylenetetramine (HMT). Hum Exp Toxicol 17:373–379PubMedCrossRefGoogle Scholar
  33. 33.
    Anderson DR, Byers SL, Vesely KR (2000) Treatment of sulfur mustard (HD)-induced lung injury. J Appl Toxicol 20(suppl 1):S129–S132PubMedCrossRefGoogle Scholar
  34. 34.
    Rappeneau S, Baeza-Squiban A, Marano F et al (2000) Efficient protection of human bronchial epithelial cells against sulfur and nitrogen mustard cytotoxicity using drug combinations. Toxicol Sci 58:153–160PubMedCrossRefGoogle Scholar
  35. 35.
    Emad A, Rezaian GR (1999) Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas induced pulmonary fibrosis. Chest 115:1346–1351PubMedCrossRefGoogle Scholar
  36. 36.
    Calvet JH, Planus E, Rouet P et al (1999) Matrix metalloproteinase gelatinases in sulfur mustard-induced acute airway injury in guinea pigs. Am J Physiol 276:L754–L762PubMedGoogle Scholar
  37. 37.
    Calvet JH, Gascard JP, Delamanche S et al (1999) Airway epithelial damage and release of inflammatory mediators in human lung parenchyma after sulfur mustard exposure. Hum Exp Toxicol 18:77–81PubMedCrossRefGoogle Scholar
  38. 38.
    Langford AM, Hobbs MJ, Upshall DG et al (1996) The effect of sulfur mustard on glutathione levels in rat lung slices and the influence of treatment with arylthiols and cysteine esters. Hum Exp Toxicol 15:619–624PubMedCrossRefGoogle Scholar
  39. 39.
    D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P (2001) CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 286:180–187PubMedCrossRefGoogle Scholar
  40. 40.
    Roberti RR, Van Tosh A, Baruchin MA et al (1994) Left ventricular cavity-to-myocardial count ratio: a new parameter for detecting resting left ventricular dysfunction directly from tomographic thallium perfusion scintigraphy. J Nucl Med 34:193–198Google Scholar
  41. 41.
    Saidova MA, Ostroumov EN, Naumov VG, Sergienko VB, Belenkov IuN (1992) The radionuclide diagnosis of dilated cardiomyopathy: a new approach to assessing myocardial perfusion function by 201Tl scintigraphic data at rest and during the performance of the dipyridamole test. Kardiologiia 32(7–8):50–55PubMedGoogle Scholar
  42. 42.
    Li PC, Sun SS, Kao A, Lin CC, Lee CC (2002) Left ventricular cavity-to-myocardium count ratio in exercise and resting technetium-99 m-tetrofosmin SPECT: correlation with left ventricular function. Int J Cardiovasc Imaging 18(5):349–352PubMedCrossRefGoogle Scholar
  43. 43.
    Sciagra R, Bisi G, Buonamici P, Zerauschek F, Santoro GM, Meldolesi U, Fazzini PF, Pupi A (1997) Left ventricular cavity-to-myocardium count ratio in technetium-99 m-sestamibi SPECT in the detection of resting left ventricular dysfunction. J Nucl Med 38(5):766–770PubMedGoogle Scholar
  44. 44.
    Maunoury C, Antonietti T, Sebahoun S, Barritault L (2001) Assessment of left ventricular function by 201Tl SPECT using left ventricular cavity-to-myocardium count ratio. Nucl Med Commun 22(3):281–285PubMedCrossRefGoogle Scholar
  45. 45.
    Singer AW, Jaax NK, Graham JS, McLeod CG Jr (1987) Cardiomyopathy in Soman and Sarin intoxicated rats. Toxicol Lett 36(3):243–249PubMedCrossRefGoogle Scholar
  46. 46.
    Ding HJ, Lin CC, Wang JJ, Ho ST, Kao A (2002) Correlation of abnormal response of left ventricular ejection fraction after exercise and left ventricular cavity-to-myocardium count ratio of technetium-99 m-tetrofosmin single photon emission computed tomography in patients with coronary artery disease. Jpn Heart J 43(5):505–514PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Ali Gholamrezanezhad
    • 1
    • 2
  • Mohsen Saghari
    • 1
  • Arsalan Vakili
    • 1
  • Sahar Mirpour
    • 1
  • Mohammad Hossein Farahani
    • 3
  1. 1.Research Institute for Nuclear MedicineTehran University of Medical SciencesTehranIran
  2. 2.Young Researchers ClubAzad University of TehranTehranIran
  3. 3.Nuclear Medicine DepartmentHeram Toseh Novin Engineering CompanyTehranIran

Personalised recommendations